X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Dr Reddy’s posts better than expected Q3 numbers but concerns remain

Content Team by Content Team
10th February 2018
in Manufacturing, Press Statements

There were two positive developments at Dr Reddy’s that were hard to miss when the company’s CFO Saumen Chakraborty and COO Abhijit Mukerjee announced the company’s financial results for the third quarter (Q3) and for the first nine months. One:

“The company had some one offs in the quarter but the US numbers have turned out to be better than what some of us expected, especially in the US,” is how a leading analyst put it.

Second: A day earlier, the company had informed the bourses that a re-inspection carried out by the German regulator at the company’s formulations making plant at Bachupally, Hyderabad, had led to the EU GMP non-compliance getting withdrawn by the government of Bavaria and this means the plant could restart dispatching its approved products to the European Union. But then, it was not as if the company was totally out of the woods for challenges remain.

It posted, what analysts, called relatively weak numbers for most regions outside US like Europe, emerging markets and even India, though there was a 3 per cent year-on-year growth in India. Then, there was a 29 per cent de-growth year-on-year in the profit at Rs 334.4 crore as against Rs 470.1 crore earlier.

But then, Chakraborty reminded that during Q3 FY18, the ‘Tax cuts and jobs act of 2017″ in the US, which had meant a hit for many Indian companies including Dr Reddy’s for the “consequent to this enactment in the US, the deferred tax assets and liabilities of its US entity were remeasured resulting in a one-time charge of Rs 93 crore.”

Disclosing the financial results for their quarter and for the first nine months of the year, Saumen Chakraborty, the CFO of the company, however referred to a 3 per cent year-on-year growth in topline and a 7 per cent sequential growth. The decline on the profit compared the previous period, he attributed mainly to the price erosion challenges that pharma companies are facing in the US. The share price of the company, which opened at Rs 2569, touched a high of Rs 2594.95 to close at Rs 2504 on Thursday.

Previous Post

Blood vessel-on-a-chips show anti-cancer drug effects in human cells

Next Post

Danish Researchers Create New Approach To Make QR-Coded Medicines

Related Posts

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
Europe

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

3rd March 2023
Canada's National Carrier Air Canada Cargo and the Cool Tech Company ColdChase join Pharma.Aero
Manufacturing

Canada’s National Carrier Air Canada Cargo and the Cool Tech Company ColdChase join Pharma.Aero

22nd February 2023
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine
Drug Development

Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China

21st February 2023
Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea
Clinical Trials

Labcorp Unveils New Name for Future Independent Clinical Development Business – Fortrea

21st February 2023
Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance
IPR Data Management

Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance

21st February 2023
Next Post

Danish Researchers Create New Approach To Make QR-Coded Medicines

Latest News

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In